Onglyza · DIN 02375842 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Onglyza (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ONGLYZA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Onglyza · DIN 02375842
Manufacturer: AstraZeneca; listing date 2012-12-21
Health Canada: Marketed since 2015-02-18 · brand ONGLYZA · ATC A10BH03 SAXAGLIPTIN · form Tablet · route Oral · ingredients SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) 2.5 MG · company Astrazeneca canada inc · schedule Prescription
Ministry pays: $1.2650 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02375842)
Source record
DIN 02375842: Onglyza
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002045; group id 754; item number 1849; lccId None; manufacturer id AZC
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $2.9370; ministry $1.2650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375842
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86124
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea.
Interchangeable products
Apo-Saxagliptin · DIN 02507471 · $1.2650
Sandoz Saxagliptin · DIN 02468603 · $1.2650
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375842
Shortage record checked October 6, 2026